None
Quote | Telix Pharmaceuticals Ltd (OTCMKTS:TLPPF)
Last: | $9.02 |
---|---|
Change Percent: | -10.07% |
Open: | $8.96 |
Close: | $9.02 |
High: | $9.02 |
Low: | $8.96 |
Volume: | 1,375 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Telix Pharmaceuticals Ltd (OTCMKTS:TLPPF)
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
Message Board Posts | Telix Pharmaceuticals Ltd (OTCMKTS:TLPPF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Telix Pharmaceuticals Ltd Company Name:
TLPPF Stock Symbol:
OTCMKTS Market:
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging Collaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Au...